RESEARCH MONOGRAPH · KDC-MN-181

Lithium Orotate

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 2 min read

Our opinion on this compound

54/100

Real lithium at micro-doses, much weaker evidence than people assume, and the orotate counter-ion is mostly marketing

Lithium orotate is one of those compounds where the marketing has run far ahead of the data, and most of the claims rest on a thin foundation that the supplement industry has been recycling for 50 years.

The claim originates with Hans Nieper in the 1970s, who proposed that orotate as a counter-ion enabled lithium to cross cell membranes more efficiently, particularly the blood-brain barrier, and therefore allowed therapeutic CNS lithium effects at much lower elemental doses than pharmaceutical lithium carbonate. Nieper produced some preclinical-grade tracer studies that were interpreted as supporting this, but the data has not held up well under modern scrutiny, and several attempts to replicate the differential bioavailability story between orotate and carbonate have failed.

Mechanistically lithium itself is well-characterized. GSK-3 beta inhibition, IMPA/IMPase inhibition, BDNF modulation, neurogenesis effects, mTOR effects. Lithium carbonate at pharmaceutical doses (150-1200mg daily, delivering ~30-225mg elemental Li) is FDA-approved for bipolar disorder with real prophylactic and antimanic effects. The interesting question is what lower elemental lithium exposures (say 1-5mg elemental from supplement doses) actually do.

The honest answer is we mostly dont know. There's some interesting epidemiology suggesting trace lithium in drinking water correlates with reduced suicide rates in populations, which could support a low-dose effect, but the supplementation literature in healthy individuals is genuinely sparse. A few small open-label series of lithium orotate in mood symptoms exist but they're not adequately controlled.

The orotate-specific claim is the weakest part. The claim that orotate enables CNS lithium delivery at 1/10th or 1/20th the elemental dose of carbonate is mostly unsupported by modern pharmacokinetic work. Orotate has its own mild pharmacology (precursor to pyrimidines, some uricosuric and cardiac effects at higher doses) but it doesnt seem to do what Nieper proposed.

Sourcing-wise lithium orotate is widely available, the salt is straightforward to produce, HPLC verification is standard. Elemental lithium content per dose is usually around 5mg per typical capsule.

Safety profile at supplement doses is OK with no signal of nephrogenic or thyroid issues at the very low elemental exposures, but those issues remain real concerns at any sustained elevated lithium exposure.

What we like: lithium itself is a real and important mood-modulating element, and the trace-lithium epidemiology is genuinely intriguing. What we dont like: the orotate-as-vehicle claim is mostly marketing, the supplement-dose human data is much thinner than people assume, and lithium of any kind is not a casual research compound.

Evidence: 30
Mechanism: 60
Reliability: 40
Safety: 60
Sourcing: 75
Value: 65
Signal: 55
Staying power: 50

Plain-language summary Intrigue 55 / 100

Lithium orotate is a complex of low-dose lithium with orotic acid. Used as a supplement at much lower doses than prescription lithium carbonate (5-20 mg vs 600-1200 mg). Some claims about better bioavailability are not well-supported. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Lithium-orotate complex

A lithium salt of orotic acid sold as a low-dose dietary supplement for mood and cognitive applications, distinct from prescription lithium carbonate.

Abstract

Lithium orotate is a salt of lithium with orotic acid (a pyrimidine biosynthesis intermediate). The compound is sold as a dietary supplement at low doses (typically 5 to 20 mg of lithium ion, vs. clinical lithium carbonate doses providing 200 to 1200 mg lithium ion for bipolar disorder). At supplement doses, lithium plasma concentrations are well below the therapeutic and toxic ranges of clinical lithium use. The pharmacology of low-dose lithium for mood and cognitive applications is debated; some epidemiological studies suggest reduced suicide rates and dementia incidence in regions with higher dietary lithium, but the magnitude is small and confounded. Reported research dose ranges in the literature are described in the source publications.

Mechanism of action

Lithium ion delivery; mechanism shared with prescription lithium (GSK-3 inhibition, IMPase inhibition) but at substantially lower exposures.

Reported research dose ranges

Reported research dose ranges in the literature.

References

Schrauzer GN. Lithium: occurrence, dietary intakes, nutritional essentiality. J Am Coll Nutr 2002.

Read the full monograph

Available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-181

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Lithium Orotate

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs